Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease ProcessesGlobeNewsWire • 08/04/22
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 07/19/22
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812GlobeNewsWire • 06/23/22
Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences ConferenceGlobeNewsWire • 06/08/22
Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 ModulationGlobeNewsWire • 06/02/22
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/13/22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/22
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022GlobeNewsWire • 05/04/22
Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022GlobeNewsWire • 05/04/22
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular DegenerationGlobeNewsWire • 04/25/22
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/25/22
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/22
Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/30/22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/22
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2022GlobeNewsWire • 03/10/22
Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative TherapeuticsGlobeNewsWire • 02/08/22
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022GlobeNewsWire • 01/10/22
Cognition Therapeutics to Participate in Next-Generation Alzheimer's Disease Panel at Virtual Biotech Showcase on January 11, 2022GlobeNewsWire • 12/21/21
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 ModulationGlobeNewsWire • 11/30/21
Cognition Therapeutics Reports Third Quarter Financial Results and Company HighlightsGlobeNewsWire • 11/18/21
Pittsburgh Life Sciences Greenhouse Proudly Announces IPO of Portfolio Company Cognition TherapeuticsPRNewsWire • 10/12/21
U.S. IPO Weekly Recap: Healthcare And Canadian Crosslistings Lead An 8 IPO WeekSeeking Alpha • 10/09/21
Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected rangeMarket Watch • 10/08/21